Quantification of vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor in plasma of cancer patients and healthy volunteers - Comparison of ELISA and microsphere-based multiplexed immunoassay

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 9, 2008, Pages 1256-1264

  Kornacker, Martin ^a   Roth, Angelika ^a   Christensen, Olaf ^b   Krätzschmar, Jörn ^a   Wensing, Georg ^a  

^a BAYER PHARMA AG   (Germany)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

Angiogenesis; Biomarker; Cancer; Growth factor; Immunoassay

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEALTH; HUMANS; IMMUNOASSAY; INTERLEUKIN-8; LINEAR MODELS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASMS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SEX CHARACTERISTICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51849133152     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.249     Document Type: Article

References (58)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
3. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
4. Kobayashi Y. Neutrophil infiltration and chemokines. Crit Rev Immunol 2006;26:307-16.
5. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
6. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54:3242-7.
7. Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, Mentha G, Ruefenacht D, Sappino AP, et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 2000;85:40-5.
8. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000;26:657-62.
9. Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997;3:647-51.
10. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003;9:5996-6001.
11. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003;120:452-6.
12. Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001;7:2675-81.
13. Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001;7:538-43.
14. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003;62:297-303.
15. Wensing G, Kuhlmann J. The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol 2006;1:185-91.
16. Rolan P, Atkinson AJ Jr, Lesko LJ. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003;73:284-91.
17. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
18. Hardwick JS, Yang Y, Zhang C, Shi B, McFall R, Koury EJ, et al. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 2005;4:413-25.
19. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102-7.
20. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Meth 2000;243:243-55.
21. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1956;1:80-3.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
23. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.
24. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
25. Selgas R, del Peso G, Bajo MA, Molina S, Cirugeda A, Sanchez-Tomero JA, et al. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent. J Nephrol 2001;14:270-4.
26. Yoshimoto A, Kasahara K, Nishio M, Hourai T, Sone T, Kimura H, et al. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. Jap J Clin Oncol 2005;35:233-8.
27. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
28. Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 2005;15:515-22.
29. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003;10:355-62.
30. Dehaven K, Taylor DD, Gercel-Taylor C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer 2002;12:715-9.
31. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997;76:238-43.
32. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8.
33. Fuksiewicz M, Kaminska J, Kotowicz B, Kowalska M, Rubach M, Pienkowski T. Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clin Chem Lab Med 2006;44:1092-7.
34. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006;70:115-25.
35. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003;39:184-91.
36. Macri A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006;11:184-93.
37. Minagawa N, Nakayama Y, Hirata K, Onitsuka K, Inoue Y, Nagata N, et al. Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res 2002;22:2957-63.
38. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, et al. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003;192:215-25.
39. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25.
40. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006;16:405-11.
41. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24:492-6.
42. Wallner G, Ciechanski A, Dabrowski A, Kozlowski M, Rolinski J, Laudanski J, et al. Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer. Folia Histochem Cytobiol 2001;39(Suppl 2):122-3.
43. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-6.
44. Lyon DE, McCain NL, Walter J, Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nursing Res 2008;57:51-8.
45. Reinsberg J, Dembinski J, Dorn C, Behrendt D, Bartmann P, van Der Ven H. Determination of total interleukin-8 in whole blood after cell lysis. Clin Chem 2000;46:1387-94.
46. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993;48:1120-8.
47. Huang JC, Liu DY, Dawood MY. The expression of vascular endothelial growth factor isoforms in cultured human endometrial stromal cells and its regulation by 17beta-oestradiol. Mol Hum Reprod 1998;4:603-7.
48. Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ. Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque. J Clin Endocrinol Metab 2005;90:5811-8.
49. Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E, Sarandakou A, Creatsas G. Changes in serum levels of vascular endothelial growth factor in males and females throughout life. J Soc Gynecol Invest 2000;7:309-12.
50. Camilla C, Mely L, Magnan A, Casano B, Prato S, Debono S, et al. Flow cytometric microsphere-based immunoassay: analysis of secreted cytokines in whole-blood samples from asthmatics. Clin Diagn Lab Immunol 2001;8:776-84.
51. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003;10:133-9.
52. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005;66:175-91.
53. Hildesheim A, Ryan RL, Rinehart E, Nayak S, Wallace D, Castle PE, et al. Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol Biomarkers Prev 2002;11:1477-84.
54. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Meth 2002;260:207-18.
55. Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW, et al. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem 2005;51:1102-9.
56. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Theisl A, Barth A, et al. Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vision 2006;12:1143-7.
57. Biagini RE, Sammons DL, Smith JP, MacKenzie BA, Striley CA, Semenova V, et al. Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin Diagn Lab Immunol 2004;11:50-5.
58. Martins TB, Burlingame R, von Muhlen CA, Jaskowski TD, Litwin CM, Hill HR. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 2004;11:1054-9.